サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1543903

糖尿病性腎症治療の世界市場

Diabetic Nephropathy Treatment

出版日
ページ情報
英文 196 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
糖尿病性腎症治療の世界市場
出版日: 2024年08月29日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

糖尿病性腎症治療の世界市場は2030年までに42億米ドルに達する見込み

2023年に31億米ドルと推定された糖尿病性腎症治療の世界市場は、2030年には42億米ドルに達し、分析期間2023-2030年のCAGRは4.7%で成長すると予測されます。本レポートで分析したセグメントの一つであるアンジオテンシン受容体拮抗薬（ARB）は、CAGR 5.9%を記録し、分析期間終了時には18億米ドルに達すると予測されます。Sodium-Glucose Cotransporter 2（SGLT2）セグメントの成長率は、分析期間中CAGR 4.5%と推定されます。

米国市場は8億190万米ドル、中国はCAGR7.6%で成長すると予測

米国の糖尿病性腎症治療市場は、2023年に8億190万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 7.6%で推移し、2030年には予測市場規模9億4,970万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.8%と3.9%と予測されています。欧州では、ドイツがCAGR 3.5%で成長すると予測されています。

世界の糖尿病性腎症治療市場- 主要動向と促進要因まとめ

糖尿病性腎症とは何か、なぜ治療が重要なのか？

糖尿病性腎症は、糖尿病性腎臓病としても知られ、一部の糖尿病患者が罹患する深刻な合併症です。糖尿病腎症は、慢性的な高血糖によって引き起こされる長期的な障害によって生じ、血液中の老廃物や余分な水分を効率的にろ過する腎臓の機能が損なわれます。時間が経つにつれて、この状態は腎不全につながる可能性があり、透析や腎移植が必要となります。病気の進行を遅らせ、予後を改善するためには、早期の診断と治療が不可欠です。治療には通常、糖尿病をより効果的に管理し、高血圧や高コレステロールなどの関連する健康問題に対処することが含まれます。アンジオテンシン変換酵素（ACE）阻害薬やアンジオテンシンII受容体拮抗薬（ARB）のような薬剤は、血圧を下げ、蛋白尿を減少させ、腎機能を保護するために一般的に処方されます。これらの治療と厳格な血糖コントロールおよび生活習慣の改善を組み合わせることが、糖尿病性腎症管理の基礎となります。

新しい治療法はどのように糖尿病性腎症治療を向上させているか？

糖尿病性腎症の治療における最近の動向は、従来の血糖コントロールを超える改善効果をもたらす新しい薬理学的薬剤の開発が中心となっています。最も有望な研究分野の1つに、ナトリウムグルコース共輸送体2（SGLT2）阻害薬の使用があります。これらの薬剤は血糖値のコントロールに役立つだけでなく、糖尿病に伴う腎臓病の進行や心血管系のリスクを軽減する可能性を示しています。SGLT2阻害薬は、グルコースの尿中排泄を促進することにより血糖値を低下させ、腎障害発症の重要な因子である糸球体内圧を低下させることで、腎臓を保護する効果があることが研究により示唆されています。さらに、GLP-1受容体作動薬の抗炎症作用や抗動脈硬化作用が腎保護に寄与する可能性があることから、糖尿病性腎症の治療におけるGLP-1受容体作動薬の利点を探ることに関心が高まっています。

糖尿病性腎症の治療において個別化医療が果たす役割とは？

個別化医療は、糖尿病性腎症の根底にある遺伝的・分子的要因の深い理解により、糖尿病性腎症の管理においてますます焦点となりつつあります。このアプローチでは、遺伝的素因、疾患の進行度、過去の治療に対する反応性などの因子を組み込んで、個々の患者のプロファイルに合わせた治療戦略を立てます。個別化された治療計画には、患者の転帰を最適化するために、薬物療法、生活習慣の調整、モニタリング戦略などが組み合わされます。先進的な診断法は個別化医療において重要な役割を果たし、ヘルスケアプロバイダーは腎症の発症と進行を重大な障害が起こる前に分子レベルで検出することができます。これらの技術により、より早期の介入とより正確な治療標的が可能となり、糖尿病患者の末期腎疾患の発症を遅らせたり、予防したりできる可能性があります。

糖尿病性腎症治療市場の成長の原動力は？

糖尿病性腎症治療市場の成長は、世界の糖尿病有病率の上昇、腎臓病早期発見の重要性に対する認識の高まり、治療オプションの進歩など、いくつかの要因によってもたらされます。糖尿病がより多くの人口に影響を与え続けるにつれ、腎臓病を含む合併症の発生率も上昇し、効果的な治療ソリューションへの需要が高まることが予想されます。SGLT2阻害薬やGLP-1受容体作動薬のような新規治療薬のイントロダクションは、治療の展望を広げ、患者に新たな希望と転帰の改善をもたらしています。さらに、個別化医療への注目の高まりと早期発見のためのバイオマーカーの開発が、治療の効率と効果を高めています。新興市場における経済成長とヘルスケア・インフラの充実も、こうした先端治療へのアクセスの向上に寄与しています。これらの要因が相まって、この分野への継続的な投資と関心が確保され、糖尿病性腎症の管理における継続的な革新と開発が推進されています。

調査対象企業の例（注目の46社）

  • Abbott Laboratories, Inc.
  • Bayer AG
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Reata Pharmaceuticals, Inc.
  • Sanofi SA

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP11512

Global Diabetic Nephropathy Treatment Market to Reach US$4.2 Billion by 2030

The global market for Diabetic Nephropathy Treatment estimated at US$3.1 Billion in the year 2023, is expected to reach US$4.2 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2023-2030. Angiotensin Receptor Blockers (ARBs), one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Sodium-Glucose Cotransporter 2 (SGLT2) segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$801.9 Million While China is Forecast to Grow at 7.6% CAGR

The Diabetic Nephropathy Treatment market in the U.S. is estimated at US$801.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$949.7 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 3.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Diabetic Nephropathy Treatment Market - Key Trends and Drivers Summarized

What Is Diabetic Nephropathy and Why Is Its Treatment Crucial?

Diabetic nephropathy, also known as diabetic kidney disease, is a serious complication that affects some individuals with diabetes. It results from long-term damage caused by chronic high blood sugar levels, which impair the kidneys' ability to filter waste and excess fluids from the blood efficiently. Over time, this condition can lead to kidney failure, necessitating dialysis or kidney transplantation. Early diagnosis and treatment are essential to slow the progression of the disease and improve outcomes. Treatment typically involves managing diabetes more effectively and addressing related health issues such as hypertension and high cholesterol. Medications like angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are commonly prescribed to lower blood pressure and reduce proteinuria, which can help protect kidney function. These interventions, combined with strict glycemic control and lifestyle modifications, form the cornerstone of managing diabetic nephropathy.

How Are Emerging Therapies Enhancing Diabetic Nephropathy Treatment?

Recent advancements in the treatment of diabetic nephropathy have centered around the development of new pharmacological agents that offer improved outcomes beyond traditional blood sugar control. One of the most promising areas of research includes the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors. These drugs not only help control blood sugar levels but also show potential in reducing kidney disease progression and cardiovascular risks associated with diabetes. Studies suggest that SGLT2 inhibitors can offer protective benefits to the kidneys by promoting glucose excretion through the urine, thereby lowering blood glucose levels and reducing intraglomerular pressure, a key factor in the development of kidney damage. Additionally, there is growing interest in exploring the benefits of GLP-1 receptor agonists in treating diabetic nephropathy due to their anti-inflammatory and anti-atherosclerotic effects, which may contribute to renal protection.

What Role Does Personalized Medicine Play in the Management of Diabetic Nephropathy?

Personalized medicine is increasingly becoming a focal point in the management of diabetic nephropathy, driven by a deeper understanding of the genetic and molecular factors underlying the disease. This approach tailors treatment strategies to individual patient profiles, incorporating factors like genetic predisposition, disease progression, and response to previous treatments. Personalized treatment plans may involve a combination of medications, lifestyle adjustments, and monitoring strategies to optimize patient outcomes. Advanced diagnostics play a key role in personalized medicine, enabling healthcare providers to detect the onset and progression of nephropathy at a molecular level before significant damage occurs. These technologies allow for earlier intervention and more precise targeting of therapies, potentially delaying or even preventing the onset of end-stage renal disease in diabetic patients.

What Drives the Growing Market for Diabetic Nephropathy Treatment?

The growth in the diabetic nephropathy treatment market is driven by several factors, including the rising prevalence of diabetes worldwide, increased awareness of the importance of early kidney disease detection, and advancements in treatment options. As diabetes continues to affect a larger segment of the population, the incidence of its complications, including kidney disease, is also expected to rise, fueling demand for effective treatment solutions. The introduction of novel therapeutic agents, such as SGLT2 inhibitors and GLP-1 receptor agonists, has expanded the treatment landscape, offering new hope and improved outcomes for patients. Additionally, the growing focus on personalized medicine and the development of biomarkers for early detection are enhancing the efficiency and effectiveness of treatments. Economic growth and better healthcare infrastructure in emerging markets also contribute to the increased accessibility of these advanced treatments. Together, these factors ensure ongoing investment and interest in the sector, driving continuous innovation and development in the management of diabetic nephropathy.

Select Competitors (Total 46 Featured) -

  • Abbott Laboratories, Inc.
  • Bayer AG
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Reata Pharmaceuticals, Inc.
  • Sanofi SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Diabetic Nephropathy Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Global Economic Update
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Incidence of Diabetes and Subsequent Kidney-Related Complications Drive Market Demand
    • Advancements in Early Diagnostic Techniques Propel Treatment Adoption
    • Increasing Global Focus on Chronic Disease Management Enhances Market Potential
    • Rising Patient Awareness About Kidney Health Spurs Market Education and Growth
    • Evolving Treatment Protocols and Clinical Practice Guidelines Impact Market Dynamics
    • Insurance Coverage and Reimbursement Policies Influence Treatment Accessibility
    • Market Opportunities Arising from Genetic Research and Personalized Medicine
    • Technological Advancements in Dialysis Equipment Enhance Treatment Efficiency
    • Increasing Prevalence of Obesity and Its Impact on Kidney Health
    • Impact of Global Aging Population on Healthcare Services and Nephropathy Treatment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Diabetic Nephropathy Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Diabetic Nephropathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Diabetic Nephropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Angiotensin Receptor Blockers (ARBs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Angiotensin Receptor Blockers (ARBs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Angiotensin Receptor Blockers (ARBs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Sodium-Glucose Cotransporter 2 (SGLT2) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Sodium-Glucose Cotransporter 2 (SGLT2) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Sodium-Glucose Cotransporter 2 (SGLT2) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Angiotensin-Converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Angiotensin-Converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Angiotensin-Converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Mineralocorticoid Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Mineralocorticoid Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Mineralocorticoid Receptor Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Drug Store & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Online by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Diabetic Nephropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • JAPAN
    • Diabetic Nephropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • CHINA
    • Diabetic Nephropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • EUROPE
    • Diabetic Nephropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Diabetic Nephropathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Diabetic Nephropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • FRANCE
    • Diabetic Nephropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • GERMANY
    • Diabetic Nephropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Diabetic Nephropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Diabetic Nephropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Diabetic Nephropathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Diabetic Nephropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Diabetic Nephropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • INDIA
    • Diabetic Nephropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Diabetic Nephropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Diabetic Nephropathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Diabetic Nephropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Diabetic Nephropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Diabetic Nephropathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Diabetic Nephropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030
  • AFRICA
    • Diabetic Nephropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Diabetic Nephropathy Treatment by Drug Class - Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Diabetic Nephropathy Treatment by Drug Class - Percentage Breakdown of Value Sales for Angiotensin Receptor Blockers (ARBs), Sodium-Glucose Cotransporter 2 (SGLT2), Angiotensin-Converting Enzyme (ACE) Inhibitors, Mineralocorticoid Receptor Antagonists and Other Drug Class for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Diabetic Nephropathy Treatment by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Diabetic Nephropathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online for the Years 2014, 2024 & 2030

IV. COMPETITION